Comparison Study of Transarterial Chemoembolization and Percutaneous Ethanol Injection for Multiple, Small HCCs

A Multicenter, Randomized, Controlled Trial of the Effective Therapy for Multiple, Small Hepatocellular Carcinomas: Comparing Transarterial Chemoembolization With Percutaneous Ethanol Injection Therapy.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00357474

Enrollment

Registered

2006-07-27

Start date

2005-10-31

Completion date

2012-02-29

Last updated

2013-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Keywords

HCC, TACE, PEIT

Brief summary

The purpose of this study is to choose the preferred treatment modality for multiple, small hepatocellular carcinomas.

Detailed description

To compare the below things between PEIT group and TACE group 1. Survival 1. 5 year overall survival rate 2. Disease free survival rate 2. Recurrence a. recurrence rate

Interventions

PROCEDURETransarterial chemoembolization

lipiodol, adriamycin and/or mitomycin

PROCEDUREPercutaneous ethanol injection therapy

99% ethanol 2-4cc per one session, two to three sessions per single procedure for one week

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Inclusion criteria

* The evidences of HBV(+) &/or HCV(+) infection or liver cirrhosis * Two to three tumor nodules with Child-Pugh classification A or single to three tumor nodules with Child-Pugh classification B * The maximal, longest diameter of tumor mass measured by CT finding should be less than 2 cm. * 1\) Only for newly detected HCCs which were not treated before or 2) If treated before, it should be noted that there is no evidence of recurrence within the latest 6 months and, and also it should be remotely recurred more than 2cm apart from primary lesion. * It should be compatible with the typical findings of HCCs radiologically(MD CT or dynamic MRI)

Exclusion criteria

* In case of hepatic vein or portal vein invasion radiologically(CT or MRI)

Design outcomes

Primary

Measure	Time frame
overall survival rate	5 year

Secondary

Measure	Time frame
Disease free survival rate and recurrence rate	5 year

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026